GlassScriptPhysician profile
Dinee M Riley
NPI 1063407377
$512.05
in general payments reported to CMS, 2019-2025
13 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $20.10 · 2024: $196 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $443 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $443.06 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $175.63 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $42.53 | 2024-2025 | Airsupra |
| Novo Nordisk INC | $39.85 | 2024 | Wegovy |
| Boston Scientific Corporation | $39.75 | 2024 | |
| Dexcom, INC. | $36.76 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $31.14 | 2024-2025 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $24.62 | 2025 | Opsumit, Uptravi |
| Medtronic, INC. | $23.69 | 2024 | Interstim |
| Philips North America LLC | $22.84 | 2025 | Vest Therapy Und |
| Abbott Laboratories | $21.98 | 2025 | Proclaim |
| Lilly USA, LLC | $20.10 | 2023 | Mounjaro |
| Sumitomo Pharma America, INC. | $19.49 | 2025 | Gemtesa |
| Currax Pharmaceuticals LLC | $13.67 | 2024 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinee Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.